Adequate therapy for herpes viral infection

Adequate therapy for herpes viral infection

In the presence of herpes infection, adequate therapy should be carried out taking into account the nature of the lesion (local, generalized form), the primary or recurrent course of the disease.

The main goal of the therapy is:

  • relief of clinical symptoms, acceleration of resolution of clinical manifestations, reduction of the affected area, reduction of general intoxication;
  • prevention of the development of an acute process or relapse,
  • reducing the frequency of relapses, shortening their duration, increasing the time period between relapses of the disease, as well as facilitating their course;
  • improving the quality of life of patients;
  • prevention of the development of complications;
  • prevention of further spread of the pathogen, reducing the risk of infection of the sexual partner or newborn.

Sex partners of patients with herpes infection (HS) of the urogenital tract should be actively identified. Treatment should Provo – dit them with clinical manifestations of herpes. It should be advised to abstain from sexual activity or to use condoms during exacerbations. Treatment should be based on lifestyle and suppression needs associated with physical and psychosocial factors.

It is important to bear in mind that achieving a positive result in the treatment of genital herpes (HH) is associated with a number of difficulties. Complete elimination of the pathogen, the herpes simplex virus (HSV), is impossible. Despite the achieved success in the treatment of HH, the existing methods do not provide complete elimination of viruses from the body.

Treatment methods for herpes infection

In the treatment of viral infections, the following methods are used:

  • use effective antiviral chemotherapy drugs;
  • use agents that increase the specific and nonspecific resistance of the body (interferon and its inductors, immunomodulators, vaccines);
  • carry out serotherapy and seroprophylaxis (treatment and prophylaxis with immune sera) using specific human immunoglobulins or immunized animals;
  • local and antiseptic agents are used to relieve mucocutaneous lesions.

Antiviral therapy for genital herpes

The following approaches to antiviral therapy exist:

  • treatment of the primary episode of HH;
  • episodic antiviral therapy (to stop each separate episode of exacerbation of GI);
  • prophylactic (preventative or suppressive) therapy (continuous treatment over a period of time to prevent relapses and prevent transmission of infection to others).

None of the known antiviral chemotherapy drugs are capable of eliminating HSV from the body.

There are a number of antiviral drugs that can quickly and effectively stop acute manifestations of genital herpes. In adequate dosage, most of these drugs are equally effective in reducing the severity and duration of exacerbations of genital herpes. However, clinical experience with their use has shown that, while alleviating the severity of the symptoms of the disease, they do not prevent the onset of relapses and, in most cases, do not reduce their frequency.

Preventive (suppressive) antiviral therapy

Numerous studies have shown that prolonged prophylactic therapy with antiviral drugs significantly reduces asymptomatic and subclinical (in the prodromal period) virus shedding.

When choosing suppressive therapy, one should take into account not only the frequency of relapses and their impact on the quality of life of an individual patient, but also the cost and inconvenience of the dosage regimen of such therapy. Rare clinically pronounced relapses will nevertheless occur in most patients and against the background of suppressive treatment. Until now, there are no systemic drugs with a long half-life that can reduce the likelihood of “breakthroughs” of infection during the period of prophylactic (suppressive) therapy.

Currently studied immunopathogenetic features of recurrent herpes infection convincingly indicate a violation of the cellular immune response in this category of patients. With herpes, immunodeficiency states develop, due to the insufficiency of various parts of the immune system. In order to achieve the normalization of immunological parameters in patients with this pathology, it is necessary to continue treatment in the inter-relapse period to correct residual immunological disorders.

An important beneficial effect of preventive therapy is the reduction of psychological pressure on patients.

Herpes vaccine

GH vaccine prophylaxis is at the stage of scientific and experimental development. So far, no effective prophylactic vaccine against HSV has been obtained. The nature of HSV infection, which consists in a local lesion followed by a latency period without systemic viremia, leads to the fact that even the successful production of specific antibodies does not protect against subsequent relapse.

The developed vaccines (live, killed and recombinant) have not found widespread use due to the lack of reliable methods for assessing the effectiveness of vaccination courses, criteria for the duration of vaccination and further rehabilitation of patients.

Genital herpes can and should be treated

Treatment of genital herpes is a multifaceted task, a complex and time-consuming process. Correct treatment and prescription of medicines can only be carried out by a qualified specialist, taking into account the diagnostics and medical history. For each patient, therapy should be selected individually. In case of a severe course of the disease, treatment in a hospital is indicated.

The result of treatment largely depends on the experience of the doctor, as well as on the patience and careful implementation of the doctor’s recommendations by the patient. The arsenal of antiviral and immune drugs existing today can solve many problems that arise in people suffering from recurrent forms of HH with damage to the genitals, buttocks and other more rare localizations. Early initiation of treatment is essential to obtain a significant antiviral effect.

Leave a Reply

Your email address will not be published. Required fields are marked *